Shots: The NICE approval is based on P-III MONALEESA-3 study results assessing Kisqali + fulvestrant vs fulvestrant as monothx. in patients with HR+/HER2- LA or metastatic breast cancer prior treated […]readmore
Tags : Novartis
Shots: The US FDA has accepted Novartis’ BLA and has granted Priority Review for crizanlizumab to prevent vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) The FDA submission […]readmore
Shots: Novartis, Amgen and Banner Alzheimer’s Institute discontinue two P-II/III studies evaluating the safety & efficacy of CNP520 for the prevention or the delay of the onset of Alzheimer’s disease […]readmore
Shots: Novartis will provide TNO155 at no cost while Mirati will sponsor the clinical study evaluating the combination therapy for solid tumors harboring KRAS G12C mutations and the companies will […]readmore
Shots: Novartis signs an exclusive commercialization agreement with Glenmark to commercialize three respiratory therapies i.e, Seebri, Onbrize and Ultibro for treating COPD in Brazil. Novartis will be responsible for the […]readmore
In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and […]readmore
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of […]readmore
Pharma
Regulatory
Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion
Shots: The positive opinion recommendation follows the study assessing arginine and lysine of same content as LysaKare, evaluating its safety and efficacy The EC will review CHMP’s opinion with its […]readmore
Shots: The study involves assessing of calcineurin-free treatment with iscalimab vs tacrolimus to test the durability of transplanted kidney grafts and improve long-term outcomes for kidney transplant patients The study […]readmore
Shots: The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg, bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation The […]readmore